Flagship Harbor Advisors’s Precision BioSciences DTIL Stock Holding History

Flagship Harbor Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-59	Closed	-$14K	–	1890
2019 Q3	$14K	Hold	59	–	–	﹤0.01%	1195
2019 Q2	$23K	Buy	+59	New	+$23.8K	﹤0.01%	1018

Other funds holding DTIL

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

ACWM

Adams Chetwood Wealth Management Durham, North Carolina $176M AUM 8.48% 1-Year Est. Return

Flagship Harbor Advisors's DTIL Position: Q4 2019 in Review

Flagship Harbor Advisors sold out of Precision BioSciences (DTIL) in Q4 2019, closing a stake of 59 shares — an estimated $14K sold.

Flagship Harbor Advisors first reported a position in DTIL in Q2 2019 and held it in 2 quarters. The position peaked at $23K in Q2 2019. 95 funds tracked by Wall St. Rank hold DTIL as of Q4 2019.

Flagship Harbor Advisors reported no remaining Precision BioSciences position as of Q4 2019 after selling out during the quarter.
Flagship Harbor Advisors sold 59 Precision BioSciences shares in Q4 2019, an estimated $14K.
Flagship Harbor Advisors first reported a position in Precision BioSciences in Q2 2019 and held it in 2 quarters.
Flagship Harbor Advisors's Precision BioSciences position peaked at $23K in Q2 2019.
95 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2019.

Based on Flagship Harbor Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.